ADAM10
MOLECULAR TARGETADAM metallopeptidase domain 10
ADAM10 (ADAM metallopeptidase domain 10) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ADAM10
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | cgs 27023a | 3.76 | 42 |
| 2 | ilomastat | 3.40 | 29 |
| 3 | Bisphenol A-Glycidyl Methacrylate | 1.10 | 2 |
| 4 | Kaempferols | 0.69 | 1 |
| 5 | Progesterone | 0.69 | 1 |
| 6 | Hexachlorophene | 0.69 | 1 |
About ADAM10 as a Drug Target
ADAM10 (ADAM metallopeptidase domain 10) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented ADAM10 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ADAM10 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.